Varner Judith A
Moores UCSD Cancer Center, La Jolla, CA 92093-0819, USA.
J Clin Invest. 2006 Dec;116(12):3111-3. doi: 10.1172/JCI30685.
The formation of new blood vessels, a process known as angiogenesis, is important for embryonic development and wound healing as well as the development of cancer and inflammation; therefore, angiogenesis is a valuable target for clinical intervention. Both logic and empiricism suggest that a balance of stimulatory and inhibitory switches is required for orderly formation of blood vessels. Thrombospondins 1 and 2 were among the first natural angiogenesis inhibitors to be identified. However, the cellular origins and mechanisms of action of these important proteins during angiogenesis have remained largely unknown. Studies by Kopp et al., presented in this issue of the JCI, clarify some of these issues by revealing that megakaryocytes and their "sticky" wound-healing progeny, platelets, are important sources of thrombospondins 1 and 2 and that these thrombopoietic cells play key roles in controlling blood vessel formation during hematopoiesis and ischemic wound healing (see the related article beginning on page 3277).
新血管的形成,即血管生成过程,对胚胎发育、伤口愈合以及癌症和炎症的发展都很重要;因此,血管生成是临床干预的一个有价值的靶点。逻辑和经验都表明,血管有序形成需要刺激和抑制开关的平衡。血小板反应蛋白1和2是最早被鉴定出的天然血管生成抑制剂。然而,在血管生成过程中,这些重要蛋白质的细胞来源和作用机制在很大程度上仍不为人知。本期《临床研究杂志》中科普等人的研究揭示,巨核细胞及其“粘性”伤口愈合后代血小板是血小板反应蛋白1和2的重要来源,并且这些血栓生成细胞在造血和缺血性伤口愈合过程中控制血管形成方面发挥关键作用,从而澄清了其中一些问题(见第3277页开始的相关文章)。